Comparison of 50 μg Oral and Vaginal Misoprostol Tablets in Induction of Labor at Term

Vineeta Yadav, Rangaiah Nagaratnamma, Nagendra Prasad

ABSTRACT

Objective: To compare efficacy and safety of 50 μg misoprostol administered vaginally, with oral route for induction of labor at term.

Materials and methods: One hundred women at term gestation, Bishop score ≤ 4, with various indications for labor induction were randomized. Fifty women received 50 μg misoprostol orally and 50 women received 50 μg vaginally, fourth hourly (maximum six doses) or till the women went into active labor.

Results: In vaginal misoprostol group, induction delivery interval was significantly less (8.70 vs 17.47 hours) and successful induction was significantly higher (70 vs 60%) than oral group, within 24 hours of induction. In vaginal group, 46% women needed two doses for delivery compared with 8% in oral group. A maximum of six doses were required.

Conclusion: Vaginal route of misoprostol is more effective in inducing labor than oral administration.

Keywords: Induction of labor, Oral misoprostol, Vaginal misoprostol.

INTRODUCTION

Induction of labor at term is a common obstetric intervention, and cervical ripening in these cases is considered to be of importance. Literature review and meta-analysis have shown that there are advantages in using vaginal prostaglandins (PGs) when compared with oxytocin alone in the presence of an unripe cervix, with regard to a shorter induction to delivery time and a lower cesarean section rate. Induction of labor at term with unfavorable cervix is associated with increased risk of failed induction and cesarean sections. Various methods for cervical ripening include oxytocin, Foley’s catheter, and others. All these methods have their own advantages and disadvantages. Hence, there is a need for more efficient inducing agent with less limitations. Till today no ideal agent has been found. Prostaglandins are new drugs of interest in this field. Out of all PGs, PGE1 and PGE2 have been tried for induction of labor. Prostaglandin E2 is being used as gel and tablet, has the advantage of being used intracervically, and vaginally, is expensive, and needs refrigeration.

Synthetic analog of PGE1, misoprostol, is originally used as gastro protective agent; its use for cervical ripening and labor induction is upcoming and is being tried enthusiastically by obstetricians worldwide. It has advantage of being cheap, stable at room temperature, and easy to be administered by various routes, i.e., vaginal, oral, sublingual, or rectal. When administered orally, absorption of the drug is erratic, and at the same time, it is more rapid than vaginally administered misoprostol, reaching peak serum concentrations within 30 minutes compared with 1 hour with vaginal route. Oral misoprostol is eliminated rapidly (2–3 hours) than vaginal (4 hours). Hence, vaginal route seems to be more efficacious than oral one and should result in shorter induction–delivery interval and reduced need for oxytocin augmentation, but at the cost of little more complications.

There have been only few trials looking at the use of oral misoprostol for the induction of labor. Bennett et al found that 50 μg of oral misoprostol effectively induced labor and Windrim et al showed that at this dose misoprostol was as effective as the other more commonly used methods of induction. Misoprostol was found to be safe and effective in patients with rupture of membranes at term.

We have taken up this study to compare administration of 50 μg misoprostol through vaginal and oral routes for cervical ripening in induction of labor.

MATERIALS AND METHODS

Research Setting

Department of Obstetrics and Gynecology, Rajarajeswari Medical College & Hospital, Bengaluru, Karnataka, India, a tertiary care teaching hospital in southern India.

Study Population

Cases are pregnant women with gestational age between 37 and 40 weeks.

1 Postgraduate Student (Third Year), 2 Professor and Head
3 Associate Professor

1-3 Department of Obstetrics and Gynecology, RajaRajeswari Medical College & Hospital, Bengaluru, Karnataka, India

Corresponding Author: Vineeta Yadav, Postgraduate Student (Third Year), Department of Obstetrics and Gynecology, RajaRajeswari Medical College & Hospital, Bengaluru, Karnataka, India, Phone: +91870074395, e-mail: Vineetayadav136@gmail.com
Sampling Frame

One hundred pregnant women were randomly assigned in the study, of which 50 cases received misoprostol orally and other 50 were given vaginally, fourth hourly, with a maximum of six doses.

Sample Size

One hundred pregnant women included in the study received misoprostol orally or vaginally.

Inclusion Criteria

Patients at term gestation, singleton pregnancy, cephalic presentation, without fetal congenital malformation, reactive fetal heart rate pattern, and Bishop score ≤ 4 were included in the study.

Exclusion Criteria

Patients with Bishop score > 4, cephalopelvic disproportion, placenta previa or unexplained vaginal bleeding, previous cesarean section or other uterine surgery, with active herpes simplex, carcinoma cervix, chorioamnionitis and contraindication to use of prostaglandins like hypersensitivity acute pelvic inflammatory disease were excluded from the study.

After detailed history of the patient, systemic and local examination were done. Blood investigations included complete blood count, human immunodeficiency virus, hepatitis B virus surface antigen, Venereal Disease Research Laboratory test, blood grouping, and Rh typing. Ultrasound of the abdomen and pelvis was conducted to rule out congenital and acquired anomalies.

After obtaining informed consent, study groups were allotted. All the enrolled parturient were divided into two groups as follows:

1. **Group I (n = 50):** Parturient who were given 50 µg misoprostol orally.
2. **Group II (n = 50):** Parturient in which 50 µg misoprostol was inserted vaginally in posterior fornix.

Both oral and vaginal tablet were repeated every fourth hourly till either patient went into active labor or maximum dose of six tablets have been consumed. Progress of labor was monitored using partogram. The uterine contractions were monitored for its frequency, intensity, and duration. Fetal heart rate and other maternal complications like nausea, vomiting, diarrhea, distress, etc., were monitored closely. Side effects of the drug like nausea, vomiting, diarrhea were treated symptomatically.

Woman was said to be in “active labor” if she had four uterine contractions per 10 minutes, lasting for 40 seconds and of good intensity which was judged subjectively.

During the course of induction, uterus was said to be hypertonic if uterine contractions lasted for >120 seconds, tachysystole if >6 contractions per 10 minutes for two consecutive 10 minutes or hyperstimulation if either or both hyper tonus tachysystole associated with abnormal fetal heart rate pattern occurred, then vaginal tablet was removed from the posterior fornix and no further dose oral or vaginal due was given.

Following data were collected.

**Baseline Data**

- Maternal age
- Socioeconomic status
- Parity
- Gestation
- Indication for induction and preinduction cervical score
- Mode of delivery
- Intrapartum and postpartum maternal and fetal complications.

**After Delivery**

- Both mother and the neonate hospital stay and complication

**Measures of Efficacy**

- Successful induction (i.e., number of women who achieved active labor within 24 hours of induction and their induction delivery interval)
- Number of deliveries within 24 hours
- Total dose of misoprostol/oxytocin required for mode of delivery.

**Measures of Safety**

- Uterine tachysystole
- Uterine hyper tonus
- Abnormal fetal heart tracings
- Incidence of meconium passage
- Neonatal outcome.

**RESULTS**

Of a total of 100 women recruited for the study, 50 women had received 50 µg misoprostol orally and 50 women received it vaginally. None of the women recruited requested to be withdrawn after enrollment. Maternal demographic characteristics and indications for induction were comparable in both the groups (Table 1). Common indication for induction of labor was hypertensive disorders in both vaginal and oral groups.

The successful induction rate was 70% in vaginal group and 60% in oral group (Table 2). Induction delivery interval was 8.70 hours (3.24–26.32) vs 17.47 hours (5–28). Also greater number of women (32/50) delivered within
Comparison of 50 µg Oral and Vaginal Misoprostol Tablets in Induction of Labor at Term

The Journal of Medical Sciences, January-March 2018;4(1):1-4

Induction delivery interval was shorter with vaginal misoprostol than with oral misoprostol (17.47 ± 5.28 vs 8.70 ± 3.24–26.32) and the highest dose required in vaginal group (70% vs 60%). Shetty et al. reported lower failure (2.4 ± 0.7 vs 6.76%, relative risk 2.7, 95% confidence interval 0.7–10.0) with 50 µg vaginal misoprostol as compared with oral misoprostol, and at the same time, reported shorter delivery interval (0.7–10.0) with 50 µg vaginal misoprostol and 100 µg oral misoprostol.

In our study, successful induction with 50 µg vaginal misoprostol was higher (70% vs 60%). Shetty et al. reported lower failure (2.4 ± 0.7 vs 6.76%, relative risk 2.7, 95% confidence interval 0.7–10.0) with 50 µg vaginal misoprostol as compared with oral misoprostol, and at the same time, reported shorter induction delivery interval by 10.1 hours.

The majority of women in both the groups (88/100) delivered vaginally (Table 4) but overall incidence of vaginal births was significantly greater in vaginal group (48/50 vs 40/50 in oral group. However, cesarean section rate was significantly more in oral group (20% vs 4%) and commonest indication for cesarean section was fetal distress in both the groups.

Lesser fetal heart rate abnormalities (Table 5) were observed with vaginal misoprostol than with oral misoprostol (2/50 vs 8/50). Incidence of uterine contractile abnormalities was more with vaginal misoprostol (7/50 vs 5/50; Table 5). Neonatal outcome in both groups was good as all the neonates were born alive with median Apgar score of 8 and 9 at 1 and 5 minutes respectively (Table 5). Two neonates from oral group required neonatal intensive care unit (NICU) admission, one for low birth weight with tachypnea and other for respiratory distress syndrome.

DISCUSSION

Misoprostol is a wonderful drug in the armamentarium of obstetricians for induction of labor. Vaginal misoprostol is an effective cervical ripener and labor-inducing agent.

In our study, successful induction with 50 µg vaginal misoprostol was higher (70% vs 60%). Shetty et al. reported lower failure (2.4 ± 0.7 vs 6.76%, relative risk 2.7, 95% confidence interval 0.7–10.0) with 50 µg vaginal misoprostol as compared with oral misoprostol, and at the same time, reported shorter induction delivery interval by 10.1 hours.

Latika and Biswajit observed 100% success rate with 50 µg vaginal misoprostol and 100 µg oral misoprostol. In our study, induction delivery interval was shorter with 50 µg vaginal misoprostol (8.70 ± 17.47 hours). While...
comparing 50 mg vaginal misoprostol with Foley’s catheter/oxytocin, successful induction was 90.61 vs 78.44% and induction delivery interval shorter by 7.87 hours in vaginal misoprostol group.13

As vaginal misoprostol is absorbed rapidly and eliminated slowly from body making, it is available to act for a longer time as compared with oral misoprostol,5 resulting in rapid progression of labor and leading to greater number of women delivering within 24 hours of induction (69.5 vs 56.4%).6 In our study, more women (64 vs 56%) in vaginal group delivered within 24 hours. Main fear with this drug is excessive uterine contractions and uterine rupture in both scarred and unscarred uterus. These complications are dose-related. The higher the dose, the more is the uterine stimulation but shorter is the induction delivery interval.7 With 50 mg vaginal misoprostol, incidence of uterine contractile abnormalities has been reported to be 4.9,9,13,12,7 and 12%. Ewert et al14 observed these complications as 3, 6.25, 10% with 25, 100, and 200 µg controlled release vaginal inserts of misoprostol. While with 50 and 100 µg oral misoprostol, uterine hyperstimulation incidence of 0.86 and 6.4%,15 respectively, are reported. Oxytocin, which has been considered safer than misoprostol,15 is also not without uterine abnormalities, with incidence being 19.2%.16 Apart from this, PGE2 also has lesser complications (12%) than misoprostol. One case of uterine rupture was reported in scarred17 and one in unscarred17 uterus with vaginal misoprostol. One case with dinoprostone3 has also been reported.

In our observation, despite high incidence of uterine contractile abnormalities with vaginal route, it does not increase cesarean section rate. In our study, oral group cesarean section rate was significantly more compared with vaginal group (20 vs 4%). In Shetty et al6 study, cesarean section rate was 24.6 vs 22.8% and in How et al,7 it was 33 vs 17%. Common indication for cesarean section in our study was fetal distress. Misoprostol and its use by vaginal and oral route does not adversely affect neonatal and maternal outcome.6,7,13

CONCLUSION

Vaginally administered 50 µg of misoprostol is a highly effective cervical ripener and labor-inducing agent than oral misoprostol.

Misoprostol when administered vaginally has a faster onset of action than the oral route in equivalent doses. But its use demands close monitoring for uterine contractile abnormalities.

REFERENCES